Brief: 1nkemia invests 75,000 euros in mesothelioma lung cancer treatment

1nkemia IUCT SA

01/02/2017 06:31

Feb 1 (Reuters) - 1nkemia IUCT Group SA  IKM.MC : 
    * Said on Tuesday decided to invest 75,000 euros ($80,858) 
in a capital increase of Applied Research Using Omic Sciences 
(Aromics) and reach 1.5 percent in the company 
    * Aromics is involved in preclinical phase of studies over 
treatment for malignant lung cancer mesothelioma, which is 
related to exposition to asbestos 
    * Says may increase its stake in Aromics once the cancer 
treatment passes preclinical phase 
 
     
 Source text: http://bit.ly/2kTtPRz 
     
 Further company coverage:  IKM.MC   
    
 
 
 
($1 = 0.9276 euros) 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))